News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
645,599 Results
Type
Article (49386)
Company Profile (231)
Press Release (595969)
Multimedia
Podcasts (164)
Webinars (25)
Section
Business (177858)
Career Advice (2605)
Deals (32772)
Drug Delivery (139)
Drug Development (79482)
Employer Resources (169)
FDA (16599)
Job Trends (13743)
News (315402)
Policy (32755)
Tag
Academia (2434)
Academic (1)
Accelerated approval (27)
Adcomms (35)
Allergies (125)
Alliances (45035)
ALS (162)
Alzheimer's disease (1706)
Antibody-drug conjugate (ADC) (299)
Approvals (16706)
Artificial intelligence (489)
Autoimmune disease (130)
Automation (26)
Bankruptcy (330)
Best Places to Work (10192)
BIOSECURE Act (23)
Biosimilars (190)
Biotechnology (116)
Bladder cancer (149)
Brain cancer (55)
Breast cancer (578)
Cancer (4394)
Cardiovascular disease (379)
Career advice (2191)
Career pathing (40)
CAR-T (257)
CDC (59)
Cell therapy (704)
Cervical cancer (34)
Clinical research (67518)
Collaboration (1444)
Company closure (5)
Compensation (1061)
Complete response letters (64)
COVID-19 (2779)
CRISPR (81)
C-suite (692)
Cystic fibrosis (137)
Data (5590)
Decentralized trials (2)
Denatured (47)
Depression (128)
Diabetes (458)
Diagnostics (5878)
Digital health (36)
Diversity (11)
Diversity, equity & inclusion (43)
Drug discovery (227)
Drug pricing (203)
Drug shortages (35)
Duchenne muscular dystrophy (222)
Earnings (73638)
Editorial (60)
Employer branding (20)
Employer resources (151)
Events (99457)
Executive appointments (926)
FDA (19376)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (17)
Funding (1255)
Gene editing (180)
Generative AI (44)
Gene therapy (569)
GLP-1 (1054)
Government (4327)
Grass and pollen (8)
Guidances (372)
Healthcare (16084)
HIV (52)
Huntington's disease (45)
IgA nephropathy (80)
Immunology and inflammation (268)
Immuno-oncology (39)
Indications (75)
Infectious disease (3028)
Inflammatory bowel disease (186)
Inflation Reduction Act (14)
Influenza (102)
Intellectual property (209)
Interviews (479)
IPO (15489)
IRA (57)
Job creations (3875)
Job search strategy (1813)
Kidney cancer (16)
Labor market (78)
Layoffs (622)
Leadership (39)
Legal (7927)
Liver cancer (90)
Longevity (13)
Lung cancer (607)
Lymphoma (344)
Machine learning (36)
Management (59)
Manufacturing (691)
MASH (163)
Medical device (11880)
Medtech (11912)
Mergers & acquisitions (18235)
Metabolic disorders (1248)
Multiple sclerosis (150)
NASH (23)
Neurodegenerative disease (295)
Neuropsychiatric disorders (83)
Neuroscience (2848)
NextGen: Class of 2025 (5536)
Non-profit (3453)
Now hiring (51)
Obesity (614)
Opinion (311)
Ovarian cancer (138)
Pain (180)
Pancreatic cancer (190)
Parkinson's disease (265)
Partnered (28)
Patents (449)
Patient recruitment (392)
Peanut (54)
People (53758)
Pharmaceutical (89)
Pharmacy benefit managers (30)
Phase I (20828)
Phase II (29320)
Phase III (22851)
Pipeline (3823)
Policy (316)
Postmarket research (2611)
Preclinical (8522)
Press Release (50)
Prostate cancer (223)
Psychedelics (52)
Radiopharmaceuticals (264)
Rare diseases (779)
Real estate (5447)
Recruiting (69)
Regulatory (24571)
Reports (42)
Research institute (2279)
Resumes & cover letters (428)
Rett syndrome (23)
RNA editing (14)
RSV (73)
Schizophrenia (145)
Series A (216)
Series B (161)
Service/supplier (14)
Sickle cell disease (97)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (45)
Startups (3370)
State (2)
Stomach cancer (19)
Supply chain (103)
Tariffs (97)
The Weekly (115)
Vaccines (1062)
Venture capital (78)
Weight loss (435)
Women's health (63)
Worklife (21)
Date
Today (109)
Last 7 days (535)
Last 30 days (2364)
Last 365 days (30258)
2025 (29790)
2024 (33900)
2023 (37955)
2022 (48576)
2021 (52355)
2020 (49729)
2019 (40556)
2018 (30958)
2017 (31273)
2016 (30064)
2015 (33726)
2014 (27398)
2013 (23039)
2012 (24702)
2011 (25296)
2010 (23250)
Location
Africa (799)
Alabama (68)
Alaska (7)
Arizona (237)
Arkansas (12)
Asia (40127)
Australia (6452)
California (10039)
Canada (2729)
China (978)
Colorado (417)
Connecticut (459)
Delaware (312)
Europe (90998)
Florida (1505)
Georgia (303)
Hawaii (3)
Idaho (47)
Illinois (729)
India (56)
Indiana (440)
Iowa (20)
Japan (373)
Kansas (108)
Kentucky (34)
Louisiana (20)
Maine (74)
Maryland (1285)
Massachusetts (7403)
Michigan (257)
Minnesota (550)
Mississippi (5)
Missouri (110)
Montana (20)
Nebraska (23)
Nevada (109)
New Hampshire (62)
New Jersey (2771)
New Mexico (26)
New York (2651)
North Carolina (1359)
North Dakota (7)
Northern California (4852)
Ohio (269)
Oklahoma (16)
Oregon (35)
Pennsylvania (1996)
Puerto Rico (17)
Rhode Island (36)
South America (1167)
South Carolina (56)
South Dakota (1)
Southern California (3900)
Tennessee (151)
Texas (1493)
United States (35805)
Utah (259)
Virginia (246)
Washington D.C. (78)
Washington State (820)
West Virginia (4)
Wisconsin (97)
Wyoming (2)
645,599 Results for "ascendis pharma a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months
If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.
December 1, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Ascendis Pharma Reports Third Quarter 2025 Financial Results
November 13, 2025
·
13 min read
Rare Diseases
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause
Therapies from industry leaders BioMarin and Ascendis Pharma supply a key hormone that promotes bone growth. In order to move the field forward, challengers are looking to address the underlying cause of the rare, genetic disease.
October 13, 2025
·
7 min read
·
Tristan Manalac
Press Releases
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
November 5, 2025
·
3 min read
Press Releases
Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference
August 28, 2025
·
3 min read
Press Releases
Ascendis Pharma Reports Second Quarter 2025 Financial Results
August 8, 2025
·
12 min read
Editorial
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top-20 pharma company. Still, there are many prominent women in pharma that could someday break through again.
September 29, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
November 26, 2025
·
4 min read
Government
How the UK’s ‘Credibility Challenge’ Hinders Attempts To Reverse Pharma’s Flight
Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, contributing to a pullback in investment.
October 1, 2025
·
4 min read
·
Nick Paul Taylor
Press Releases
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
July 31, 2025
·
3 min read
1 of 64,560
Next
